BioPorto A/S (CPH:BIOPOR), a diagnostic testing company, announced Wednesday that it was bringing on a new chief medical officer.
Christopher Bird joins the company from Roche Diagnostics Corp, a medical and scientific affairs organization where he oversaw all clinical education, non-registrational study management and field support operations.
Shares slipped 0.3% in Copenhagen.
READ: BioPorto submits FDA application for approval of its proprietary kidney-injury test for use in children
In his new role, Bird will lead the company’s development of diagnostic products, contribute to the regulatory application process and facilitate conversations with the scientific advisory board.
“I am very pleased with the appointment of Christopher Bird as CMO and welcome him to our global leadership team,” CEO Peter Eriksen said. “Moving ahead with execution of our horizontal and vertical growth strategy, Chris will be a crucial asset for us to develop more product candidates and take them through the regulatory approval process.”
BioPorto is a Denmark-based company that provides diagnostic tests and antibodies to clinicians and researchers around the world.
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel